Activated platelets targeted drug therapy

Research Opportunity
PhD students, Masters by Research, Honours students
Department
Baker Department of Cardiometabolic Health
Location
Baker Heart and Diabetes Institute
Primary Supervisor Email Number Webpage
Dr Xiaowei Wang xiaoweiw@unimelb.edu.au Personal web page
Co-supervisor Email Number Webpage
Professor Karlheinz Peter karlheinz.peter@unimelb.edu.au +61 3 8532 1490
Dr Laura Bienvenu laura.bienvenu@unimelb.edu.au

Summary Developing a novel targeted fibrinolytic drug that is directed against activated platelets. Fibrinolysis is a valuable alternative for treating myocardial infarction when an invasivesurgical procedure is not available in a timely fashion.

Project Details

Acute thrombosis causes vessel occlusion resulting in ischemic complications, such as myocardial infarction and stroke, and is a major cause of death and disability worldwide. Fast and effective removal breakdown of thrombosis is crucial to reduce injury and improve recovery.

Fibrinolysis  is  a  valuable  alternative  for  the  treatment  of  myocardial  infarction  when invasivesurgical procedure  is  not  available in a timely fashion.  For  acute  ischemic  stroke, fibrinolysis  is  the  only  treatment  option  with  a  very  narrow  therapeutic  window. However, clinically approved thrombolytics have significant drawbacks, including bleeding complications due to the high systemic concentration required. Thus their use is highly restricted leaving many patients untreated.

This project would focus on the development of novel targeted fibrinolytic drug that is directed against activated platelets. The use of small recombinant antibodies for diagnostic molecular imaging and targeted drug delivery is well established in our lab.

When thrombosis occurs, platelets are activated and aggregate together to form a thrombus. Our targeted fibrinolytic drug will locate these activated platelets and accumulate at the site of the clot where they will act to break the clot down. This allows a high potency of drugs for efficient and safe thrombolytic treatment. Due to the targeting properties, we can reduce the concentration of drugs needed, which would also enable us to eliminate the current bleeding complications associated with the clinically used fibrinolytic drugs.

Significance:b This project will develop and test a novel fibrinolytic agent with the capability to overcome  the  current  limitations  in  thrombolytic  therapy  associated  with  the  risk  of  bleeding complications.  It  has  the  potential  to  break  the  fatal  link  between  increased  fibrinolytic potency  and bleeding complications.


School Research Themes

Cardiometabolic



Research Opportunities

PhD students, Masters by Research, Honours students
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research

Graduate Research application

Honours application

Key Contact

For further information about this research, please contact a supervisor.

Department

Baker Department of Cardiometabolic Health

Research Node

Baker Heart and Diabetes Institute

MDHS Research library
Explore by researcher, school, project or topic.